Clinical Trial Update: Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sasanlimab as maintenance therapy after neoadjuvant treatment in molecularly categorized muscle-invasive bladder cancer; not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• Sasanlimab (sasanlimab)

Snippet

Sponsor: Fundación de investigación HM | Conditions: Mibc, Muscle Invasive Bladder Cancer | Phase 2 | Status: NOT_YET_RECRUITING